Charles River To Merge With Leading Chinese Drug CRO WuXi PharmaTech If $1.6 Billion Transaction Is Approved By Beijing's Antitrust Czars
This article was originally published in PharmAsia News
Executive Summary
BEIJING - With the globe's top pharmaceutical players outsourcing ever-expanding chunks of early-stage research to China, the Massachusetts-based Charles River Laboratories has launched a move to merge with China's leading contract research organization, WuXi PharmaTech, in a $1.6 billion transaction
You may also be interested in...
Asia Spotlight: WuXi PharmaTech Founder Ge Li On Merger With Charles River
On the second Monday of each month, "The Pink Sheet" provides exclusive news and commentary on the Asia biopharma market from the editors of its affiliated online publication, PharmAsia News. Register at 1PAN_Trial_LP.html"http://pharmasianews.elsevierbi.com/ PAN_Trial_LP.html for a free trial.
Asia Spotlight: WuXi PharmaTech Founder Ge Li On Merger With Charles River
On the second Monday of each month, "The Pink Sheet" provides exclusive news and commentary on the Asia biopharma market from the editors of its affiliated online publication, PharmAsia News. Register at 1PAN_Trial_LP.html"http://pharmasianews.elsevierbi.com/ PAN_Trial_LP.html for a free trial.
WuXi PharmaTech Founder Ge Li Says Upcoming Merger With Charles River Is Part Of Globalization Of The Drive To Save Lives
BEIJING - The chief executive officer of Shanghai-headquartered WuXi PharmaTech, Ge Li, said that a planned merger with Massachusetts-based contract research organization Charles River could help spark a "revolution" in early-stage drug research in China